Healthcare Industry News: HSMN NewsFeed

Devices Gastroenterology

 News Release - February 22, 2024

Lancet Digital Health Study Confirms MAGENTIQ-COLO(TM) AI-aided Colonoscopy Technology Improves Adenoma Detection Rates

Research in prestigious journal places novel polyp detection system at highest level of performance in AI-aided colonoscopy category

HAIFA, Israel, Feb. 22, 2024 -- (Healthcare Sales & Marketing Network) -- MAGENTIQ-EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal.

The study, titled "A novel computer-aided polyp detection system in screening and surveillance colonoscopy: an international multicentre, randomised, tandem trial," was performed over a period of 14 months across 10 leading medical centers, 31 endoscopists, and 952 screened and enrolled patients.

The research validates that MAGENTIQ-COLO is at the highest level of performance in the AI-aided colonoscopy category. The study shows that using MAGENTIQ-COLO™ increases adenoma detection rate (ADR) by 7% in absolute values. Increased ADR is believed to have a strong connection to the decrease in colorectal cancer (CRC) occurrence and patient mortality. In addition to ADR, the study also measured MAGENTIQ-COLO's impact on adenoma miss rate (AMR), and showed that with MAGENTIQ-COLO, AMR was 17% lower in absolute values.

"We are honored to be published by Lancet Digital Health, a journal with a phenomenal worldwide reputation for circulating innovative, practice-changing research," said Dror Zur, Founder & CEO, MAGENTIQ EYE. "It is important to note that measuring changes in both ADR and AMR in a single study is a novelty. In addition to FDA approval that we received last year, this milestone is a testament to the impact of MAGENTIQ-COLO™ in advancing the quality of colonoscopy and setting new healthcare standards in order to save more and more lives."

Link to the study

According to the U.S. National Institutes of Health, CRC ranks as the nation's third-leading cause of cancer-related deaths. CRC usually originates from the presence of polyps or other precancerous growths in the colon or rectum that can be detected during colonoscopy, a screening and surveillance process that involves inserting an endoscope equipped with a camera at its tip through the rectum and navigating along the entire length of the colon in search of abnormalities.

Although colonoscopy has become the standard of care in most developed countries, with 15 to 20 million procedures performed annually in the U.S. alone, high missed rates and undetected adenoma during colonoscopy procedures means that even patients who are regularly screened are still at risk of developing colon cancer. A missed polyp can lead to interval cancer, which accounts for approximately 8% to 10% of all CRC in the U.S. and translates to over 13,500 cancer cases that could be prevented every year with better detection.

MAGENTIQ-COLO™ is marketed in the U.S. and Europe. For more information, please contact info@magentiq.com

About MAGENTIQ-EYE Ltd.

Founded in 2014, MAGENTIQ-EYE offers a groundbreaking AI aided colonoscopy solution that offers performance at the highest level known today. With worldwide recognition from the gastroenterology community, and dozens of procedures performed every day with the assistance of MAGENTIQ-COLO™, we are setting the new standard of colonoscopy, and saving more and more lives.


Source: MAGENTIQ-EYE

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.